← Leaderboards
Robert F Place
Mirecule, Inc.
$705,341
Attributed
$1,410,681
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2017–20$1M$750K$500K$250K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$1,410,681 · 2
By mechanism
U44$1,000,000 · 1
U43$410,681 · 1
Top collaborators
- Esther H Chang3 shared
- Anthony D Saleh1 shared
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoMalignant NeoplasmsHalf-LifeIgf1r GeneGene DeletionBaseEffective TherapyGrowth Factor ReceptorsDoseHead And Neck Squamous Cell CarcinomaEpidermal Growth Factor ReceptorExtracellular MatrixCancer CellCancer TherapyAnimalsDna Sequence AlterationBiologicalCellsCetuximabAdhesionsDrug ResistanceCisplatinEncapsulatedMessenger Rna
Grant awards (4)
Novel Targeted Nanomedicine Delivering MicroRNA-30-5p ReplacementTherapy for Multi-drug Resistant Cancer Treatment$1,000,000
U44 · FY2020 · CA · contact PI
A Novel Targeted Nanomedicine Delivering MicroRNA-30-5p Replacement Therapy for Multi-drug Resistant Cancer Treatment$61,463
U43 · FY2019 · CA · contact PI
A Novel Targeted Nanomedicine Delivering MicroRNA-30-5p Replacement$49,951
U43 · FY2018 · CA · contact PI
A Novel Targeted Nanomedicine Delivering MicroRNA-30-5p Replacement Therapy for Multi-drug Resistant Cancer Treatment$299,267
U43 · FY2017 · CA · contact PI